Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05008575
Other study ID # CD33 CAR NK-AML
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 23, 2021
Est. completion date December 1, 2023

Study information

Verified date December 2021
Source Xinqiao Hospital of Chongqing
Contact Xi zhang, MD/PhD
Phone 13808310064
Email zhangxxi@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CAR technology has been used in T cell therapy and gets great success in treating hematological diseases. Following models of CAR T cells, CAR NK cell therapy has been one hot point. For myeloid malignancies, CD33 is widely expressed. Targeting CD33 surface antigens by CAR NK cells provides an off-the-shelf immune cell therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 27
Est. completion date December 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. ECOG performance status score = 2. 2. Life expectancy = 12 weeks from the time of enrollment. 3. Disease status at the time of enrollment: -Patients with AML (except M3) who have not achieved complete remission after standard chemotherapy regimens; -Not suitable or unconditional for allogeneic hematopoietic stem cell transplantation; -Patients with recurrent acute myeloid leukemia after autologous hematopoietic stem cell transplantation without active graft-versus-host disease (GVHD). 4. CD33 expression must be detected on greater than 50% of the malignant cells by immunohistochemistry or greater than 80% by flow cytometry. 5. Adequate main organ function as assessed by the following laboratory requirements: creatinine = 2.5 × upper limit of normal, cardiac ejection fraction = 40%, oxygen saturation = 90%, total bilirubin = 3 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 × upper limit of normal, Hgb=80g/L. 6. Without history of accepting anti-cancer therapy, including chemotherapy, radiotherapy, immunotherapy (immune suppressive drugs or corticosteroid treatment) within 4 weeks of screening. 7. Women of child-bearing age must have evidence of negative pregnancy test. 8. Subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol. 9. After discussion by the expert group, the patient's condition was analyzed and combined with the general physical condition of the patient, the benefit of participating in the clinical trial was greater than the risk. 10. All participants must have the ability to understand and willingness to sign a written informed consent. Exclusion Criteria: 1. Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded. 2. Active acute or chronic GVHD or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment. 3. Have been diagnosed with or treated other malignant tumors other than AML within 5 years before screening, except for the following conditions: participants with adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer; or received radical treatment Local prostate cancer, ductal carcinoma in situ. 4. There are serious systemic diseases: New York Heart Association (NYHA) stage III or IV congestive heart failure; cerebrovascular accident or myocardial infarction or hemodynamic instability caused by arrhythmia within 6 months before signing the informed consent; impaired cardiac function (LVEF<50%) assessed by echocardiographic scan. 5. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection. 6. Pregnant or lactating women. 7. Subjects with radiologically-detected CNS chloromas or CNS 3 disease (presence of = 5/µL white blood cells (WBCs) in cerebral spinal fluid (CSF) and cytospin positive for blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS leukemia such as a cranial nerve palsy from active disease). Subjects with adequately treated CNS leukemia are eligible. 8. Human immunodeficiency virus (HIV) seropositivity; hepatitis B surface antigen is positive or HBV DNA is higher than the detection limit of the analysis method; hepatitis C antibody is positive or HCV RNA is higher than the detection limit of the analysis method; syphilis antibody and syphilis rapid plasma reagin are positive; CMV DNA is positive. 9. Patients who suffer from allergies for any cytokines or antibodies. 10. Contraindications for fludarabine or cyclophosphamide treatment. 11. Receiving corticosteroids at >20 mg daily prednisone dose or equivalent. 12. Drug abuse and addiction. 13. History of mental disorders. 14. Other patients that researchers considered unsuitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
anti-CD33 CAR NK cells
6×10^8, 12×10^8, 18×10^8/KG Treatment follows a lymphodepletion
Drug:
Fludarabine
recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.
Cytoxan
recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.

Locations

Country Name City State
China Department of Hematology, Xinqiao Hospital Chongqing Chongqing

Sponsors (2)

Lead Sponsor Collaborator
Xinqiao Hospital of Chongqing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Remission Rate (ORR) Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CRi), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies 4 weeks after infusion
Primary incidence of participants with dose limiting toxicity (DLT) To characterize the safety, tolerability of Anti-CD33 CAR NK cells within 4 weeks after infusion
Secondary Progression-free survival (PFS) up to 2 years after infusion
Secondary Overall Response Rate (ORR) up to 2 years after infusion
Secondary Overall survival(OS) up to 2 years after infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05319587 - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Active, not recruiting NCT04090736 - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy Phase 3
Completed NCT01617226 - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS Phase 2
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Terminated NCT00957580 - Trial of Pimasertib in Hematological Malignancies Phase 2
Completed NCT00640796 - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors Phase 1
Completed NCT00458250 - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H Phase 1
Active, not recruiting NCT05424380 - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS Phase 1
Completed NCT01690624 - BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse Phase 1
Recruiting NCT05471700 - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients Phase 1/Phase 2
Not yet recruiting NCT05016063 - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Early Phase 1
Not yet recruiting NCT04450784 - ObServatory Children Acute RElated Therapy Leukemia
Recruiting NCT04265963 - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT04968860 - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Terminated NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Phase 1
Recruiting NCT05453903 - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Phase 1
Completed NCT03720366 - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients Phase 1
Withdrawn NCT04230564 - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1